Clinical trial

S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia

NCT00093418 · National Cancer Institute (NCI), NIH · Completed

Key facts

NCT number NCT00093418
Title S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
Official title Phase II Studies of Two Different Schedules and Two Different Doses of the Farnesyl Transferase Inhibitor R115777 (Tipifarnib, Zarnestra®, NSC-702818) for Previously Untreated Acute Myeloid Leukemia (AML) in Patients of Age 70 or Older
Lead sponsor National Cancer Institute (NCI), NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13 and 10 more
Intervention type Drug
Interventions tipifarnib
Enrollment 296
Start date Sep 1, 2004
Primary completion Jun 1, 2006
First posted Oct 8, 2004
Last update posted Jan 15, 2013
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies